Novo submits new weekly insulin for marketing clearance
![The registration submission is based on the Onwards study with more than 4,000 participants | Photo: Tidsvilde Stine/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/15747024/3rbq9o/ALTERNATES/schema-16_9/20160929-062241-pf-4924x2768ma.jpg)
Danish drugmaker Novo Nordisk has during April requested that health authorities in the EU, US and China approve the company’s new once-weekly insulin for type 1 and 2 diabetes, insulin icodec, according to Novo’s financial report for the first quarter published on Thursday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.